Past Tuesday Talks: How to Build a Company and Tackle the Toughest Diseases

Tuesday, January 31, 2023

Presented by Seema Kumar, CEO, Cure

Thank you for joining us as pioneering entrepreneur, investor, and former Genzyme executive Jim Geraghty shared his extensive and ground-breaking experiences building and fostering Biotech companies large and small—and how they overcame the many hurdles faced in developing treatments for rare but serious diseases.

Jim talked about his new book, Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology (Cold Spring Laboratory Press), which Nature called “[An] informative, sometimes passionate account [that] mixes patients’ struggles with business, medicine, politics and technology.”

Tuesday Talks: Lessons Learned From Pioneering Biotech Companies

When: Tuesday, January 31, 4:30 pm – 6:30 pm
Where: Rooftop at Cure. 345 Park Avenue South, New York, NY 10010

Topic: A fireside chat discussing the experiences gained in the world of building Biotech companies and Jim Geraghty’s latest book, “Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology.”

Speakers: Jim Geraghty, Experienced biotech board director and chair. Moderated by Seema Kumar, CEO of Cure

Featured Speakers

About Seema Kumar

Ms. Kumar joins Cure from Johnson & Johnson where she spent nearly 20 years in senior leadership positions, most recently serving as Global Head of the Office of Innovation, Global Health and Scientific Engagement. During her tenure, she led the launch of the company’s Innovation Centers, JLABS and Global Public Health initiatives, as well as the CoLaboratory at the World Economic Forum at Davos and the award winning COVID-19 educational broadcast program, “The Road to a Vaccine.”

About Jim Geraghty

Jim Geraghty has been a strategic leader in biotechnology company building and board governance for over thirty years. Today he chairs the boards of Orchard Therapeutics and Pieris Pharmaceuticals and serves on the boards of Voyager Therapeutics, Fulcrum Therapeutics, and CANbridge. He is a director of BIO Ventures for Global Health (BVGH), a global health nonprofit. Jim was earlier an Entrepreneur in Residence at Third Rock Ventures, a leading life sciences company creation fund, and Senior VP, Global Strategy, at Sanofi, a top-5 pharma company. Jim spent over 20 years at Genzyme, a pioneering biotech company, as President of Genzyme Transgenics to Genzyme Europe, and in many other roles. He started his career as a strategy consultant at Bain and is a graduate of the Yale Law School with a master's in psychology from Penn and a bachelor's from Georgetown.